JP6302673B2 - フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 - Google Patents

フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 Download PDF

Info

Publication number
JP6302673B2
JP6302673B2 JP2013549812A JP2013549812A JP6302673B2 JP 6302673 B2 JP6302673 B2 JP 6302673B2 JP 2013549812 A JP2013549812 A JP 2013549812A JP 2013549812 A JP2013549812 A JP 2013549812A JP 6302673 B2 JP6302673 B2 JP 6302673B2
Authority
JP
Japan
Prior art keywords
cancer
hours
treatment
bal27862
bubr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013549812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505877A (ja
JP2014505877A5 (https=
Inventor
ラーネ，ハイディ・アレクザンドラ
バッハマン，フェリクス
ブルルー，マドライナ
ブトロス，ミヒャエル
ギルベルト，ダニエル
ツァン，シャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
Basilea Pharmaceutica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica AG filed Critical Basilea Pharmaceutica AG
Publication of JP2014505877A publication Critical patent/JP2014505877A/ja
Publication of JP2014505877A5 publication Critical patent/JP2014505877A5/ja
Application granted granted Critical
Publication of JP6302673B2 publication Critical patent/JP6302673B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
JP2013549812A 2011-01-21 2012-01-19 フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 Expired - Fee Related JP6302673B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11151677.9 2011-01-21
EP11151677 2011-01-21
PCT/EP2012/050818 WO2012098207A1 (en) 2011-01-21 2012-01-19 Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles

Publications (3)

Publication Number Publication Date
JP2014505877A JP2014505877A (ja) 2014-03-06
JP2014505877A5 JP2014505877A5 (https=) 2015-03-12
JP6302673B2 true JP6302673B2 (ja) 2018-03-28

Family

ID=43920866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549812A Expired - Fee Related JP6302673B2 (ja) 2011-01-21 2012-01-19 フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用

Country Status (12)

Country Link
US (2) US10222377B2 (https=)
EP (1) EP2666016B1 (https=)
JP (1) JP6302673B2 (https=)
CN (1) CN103314295B (https=)
AU (1) AU2012208520B2 (https=)
CA (2) CA2822491C (https=)
DK (1) DK2666016T3 (https=)
ES (1) ES2620582T3 (https=)
HU (1) HUE032643T2 (https=)
PL (1) PL2666016T3 (https=)
PT (1) PT2666016T (https=)
WO (1) WO2012098207A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691533B1 (en) * 2011-03-29 2017-04-05 Basilea Pharmaceutica AG Use of phospho-akt as a biomarker of drug response
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
WO2017068182A1 (en) 2015-10-22 2017-04-27 Basilea Pharmaceutica Ag Use of eb1 as a biomarker of drug response
MX2021011775A (es) 2017-04-26 2023-01-10 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
US11633383B2 (en) 2017-05-16 2023-04-25 Basilea Pharmaceutica International AG Dosage principle for drugs useful for treating neoplastic diseases
CN107119137B (zh) * 2017-05-26 2018-04-06 广州华弘生物科技有限公司 一种快速检测HER‑2/neu基因表达的检测试剂盒
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489137B2 (en) * 1997-06-11 2002-12-03 Chiron Corporation Detection of loss of the wild-type huBUB1 gene
AU1614099A (en) 1997-12-01 1999-06-16 Fox Chase Cancer Center Novel genes encoding proteins involved in mitotic checkpoint control and methodsof use thereof
CA2438092C (en) * 2001-02-21 2011-08-09 Chiron Corporation Ttk in diagnosis and as a therapeutic target in cancer
MXPA05006920A (es) * 2002-12-24 2006-02-10 Astrazeneca Ab Compuestos de quinazolina.
WO2004103994A1 (en) * 2003-05-23 2004-12-02 Basilea Pharmaceutica Ag Furazanobenzimidazoles
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US8021831B2 (en) * 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
SG156625A1 (en) * 2004-12-08 2009-11-26 Aventis Pharma Inc Method for measuring resistance or sensitivity to docetaxel
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
MX2010013843A (es) * 2008-06-26 2011-01-21 Nerviano Medical Sciences Srl Pirazolo-quinazolinas.
UA106763C2 (uk) * 2009-07-27 2014-10-10 Базілеа Фармас'Ютіка Аг Фуразанобензимідазоли як проліки для лікування пухлинних або аутоімунних захворювань

Also Published As

Publication number Publication date
CA3142576A1 (en) 2012-07-26
ES2620582T3 (es) 2017-06-29
JP2014505877A (ja) 2014-03-06
HUE032643T2 (en) 2017-10-30
US20160320397A1 (en) 2016-11-03
US20140045897A1 (en) 2014-02-13
AU2012208520B2 (en) 2016-03-10
US9970938B2 (en) 2018-05-15
CN103314295B (zh) 2016-03-16
CA2822491C (en) 2023-02-14
EP2666016B1 (en) 2017-01-04
PL2666016T3 (pl) 2017-07-31
DK2666016T3 (en) 2017-04-10
NZ611805A (en) 2015-05-29
HK1189056A1 (zh) 2014-05-23
WO2012098207A1 (en) 2012-07-26
CA2822491A1 (en) 2012-07-26
AU2012208520A1 (en) 2013-07-04
US10222377B2 (en) 2019-03-05
PT2666016T (pt) 2017-04-03
CN103314295A (zh) 2013-09-18
EP2666016A1 (en) 2013-11-27

Similar Documents

Publication Publication Date Title
JP6295081B2 (ja) フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用
JP6302673B2 (ja) フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用
JP6270481B2 (ja) フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｇｌｕ−チューブリンの使用
JP6334393B2 (ja) 薬物応答のバイオマーカーとしてのホスホＡｋｔの使用
JP6302674B2 (ja) フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用
AU2012208521B9 (en) Use of stathmin as a biomarker of drug response to furazanobenzimidazoles
HK1189056B (en) Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
HK1185947B (en) Use of stathmin as a biomarker of drug response to furazanobenzimidazoles
HK1189633A (en) Use of phospho-akt as a biomarker of drug response
NZ611805B2 (en) Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
HK1189633B (en) Use of phospho-akt as a biomarker of drug response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180305

R150 Certificate of patent or registration of utility model

Ref document number: 6302673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees